Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  de Souza, Brian ^a,b   Okomo, Uduak ^c   Alexander, Neal D ^a   Aziz, Naveed ^d   Owens, Benjamin M J ^d   Kaur, Harparkash ^a   Jasseh, Momodou ^a   Muangnoicharoen, Sant ^e   Sumariwalla, Percy F ^f   Warhurst, David C ^a   Ward, Stephen A ^e   Conway, David J ^a,c   Ulloa, Luis ^g   Tracey, Kevin J ^g   Foxwell, Brian M J ^f   Kaye, Paul M ^d   Walther, Michael ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^d UNIVERSITY OF YORK   (United Kingdom)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g North Shore LIJ Research Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; AKTIVKOHLE; ARTESUNATE; DIHYDROARTEMISININ; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BRAIN MALARIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOMODULATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PROTECTION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHARCOAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALARIA, CEREBRAL; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PLASMODIUM BERGHEI; SURVIVAL RATE;

ARTESUNATE; MUS;

EID: 79958824615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009867     Document Type: Article

References (46)

1. WHO World Malaria Report. 2008. http://whqlibdoc.who.int/publications/2008/9789241563697_eng.pdf.
2. Cranston HA, Boylan CW, Carroll GL, Sutera SP, Williamson JR, et al. (1984) Plasmodium falciparum maturation abolishes physiologic red cell deformability. Science 223: 400-403.
3. Dondorp AM, Angus BJ, Hardeman MR, Chotivanich KT, Silamut K, et al. (1997) Prognostic significance of reduced red blood cell deformability in severe falciparum malaria. Am J Trop Med Hyg 57: 507-511.
4. Baruch DI, Pasloske BL, Singh HB, Bi X, Ma XC, et al. (1995) Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82: 77-87.
5. Berendt AR, Tumer GD, Newbold CI (1994) Cerebral malaria: the sequestration hypothesis. Parasitol Today 10: 412-414.
6. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, et al. (1995) Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82: 101-110.
7. Clark IA, Cowden WB (2003) The pathophysiology of falciparum malaria. Pharmacol Ther 99: 221-260.
8. Schofield L, Mueller I (2006) Clinical immunity to malaria. Curr Mol Med 6: 205-221.
9. Clark IA, Budd AC, Alleva LM (2008) Sickness behaviour pushed too far-the basis of the syndrome seen in severe protozoal, bacterial and viral diseases and post-trauma. Malar J 7: 208.
10. van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, et al. (1996) The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 174: 1091-1097.
11. Kellum JA, Venkataraman R (2002) Blood purification in sepsis: an idea whose time has come? Crit Care Med 30: 1387-1388.
12. Jackson GD, Dai Y, Sewell WA (2000) Bile mediates intestinal pathology in endotoxemia in rats. Infect Immun 68: 4714-4719.
13. Schulman G (2006) A nexus of progression of chronic kidney disease: charcoal, tryptophan and profibrotic cytokines. Blood Purif 24: 143-148.
14. Dondorp A, Nosten F, Stepniewska K, Day N, White N (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725.
15. Armitage P, Berry G, Matthews JNS (2001) Statistical methods in Medical Research. Oxford: Blackwell Scientific Publications.
16. van Belle G, Martin DC (1993) Sample size as a function of coefficient of variation and ratio of means. American Statistician 47: 163-167.
17. Hunt NH, Grau GE (2003) Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 24: 491-499.
18. Engwerda CR, Ato M, Cotterell SE, Mynott TL, Tschannerl A, et al. (2002) A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol 161: 429-437.
19. Hearn J, Rayment N, Landon DN, Katz DR, de Souza JB (2000) Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature. Infect Immun 68: 5364-5376.
20. de Souza JB, Riley EM (2002) Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 4: 291-300.
21. Riley EM, Wahl S, Perkins DJ, Schofield L (2006) Regulating immunity to malaria. Parasite Immunol 28: 35-49.
22. Schofield L, Grau GE (2005) Immunological processes in malaria pathogenesis. Nat Rev Immunol 5: 722-735.
23. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, et al. (2007) Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 204: 273-283.
24. Akintonwa A, Orisakwe OE (1990) The adsorption of quinine and quinidine to activated charcoal with and without magnesium sulfate. Vet Hum Toxicol 32: 567-568.
25. Lockey D, Bateman DN (1989) Effect of oral activated charcoal on quinine elimination. Br J Clin Pharmacol 27: 92-94.
26. Prescott LF, Hamilton AR, Heyworth R (1989) Treatment of quinine overdosage with repeated oral charcoal. Br J Clin Pharmacol 27: 95-97.
27. Griffith JW, O'Connor C, Bernard K, Town T, Goldstein DR, et al. (2007) Tolllike receptor modulation of murine cerebral malaria is dependent on the genetic background of the host. J Infect Dis 196: 1553-1564.
28. Penet MF, Abou-Hamdan M, Coltel N, Cornille E, Grau GE, et al. (2008) Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci U S A 105: 1321-1326.
29. Serghides L, Patel SN, Ayi K, Lu Z, Gowda DC, et al. (2009) Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J Infect Dis 199: 1536-1545.
30. Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, et al. (2009) Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 49: 841-849.
31. Delahaye NF, Coltel N, Puthier D, Flori L, Houlgatte R, et al. (2006) Geneexpression profiling discriminates between cerebral malaria (CM)-susceptible mice and CM-resistant mice. J Infect Dis 193: 312-321.
32. Lovegrove FE, Gharib SA, Patel SN, Hawkes CA, Kain KC, et al. (2007) Expression microarray analysis implicates apoptosis and interferon-responsive mechanisms in susceptibility to experimental cerebral malaria. Am J Pathol 171: 1894-1903.
33. Lovegrove FE, Pena-Castillo L, Mohammad N, Liles WC, Hughes TR, et al. (2006) Simultaneous host and parasite expression profiling identifies tissuespecific transcriptional programs associated with susceptibility or resistance to experimental cerebral malaria. BMC Genomics 7: 295.
34. Chakravorty SJ, Carret C, Nash GB, Ivens A, Szestak T, et al. (2007) Altered phenotype and gene transcription in endothelial cells, induced by Plasmodium falciparum-infected red blood cells: pathogenic or protective? Int J Parasitol 37: 975-987.
35. Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, et al. (2005) Genomewide analysis of the host response to malaria in Kenyan children. J Infect Dis 191: 1599-1611.
36. Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, et al. (2006) Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. Infect Immun 74: 5561-5573.
37. He XS, Ji X, Hale MB, Cheung R, Ahmed A, et al. (2006) Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44: 352-359.
38. Wang E, Marincola FM (2008) Bottom up: a modular view of immunology. Immunity 29: 9-11.
39. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29: 150-164.
40. Bradberry SM, Vale JA (1995) Multiple-dose activated charcoal: a review of relevant clinical studies. J Toxicol Clin Toxicol 33: 407-416.
41. Hasan MM, el-Sayed YM, Abdelaziz AA (1990) The effect of oral activated charcoal on the systemic clearance of gentamicin in rabbits with acute renal failure. J Pharm Pharmacol 42: 85-88.
42. Berkley J, Mwangi I, Griffiths K, Ahmed I, Mithwani S, et al. (2005) Assessment of severe malnutrition among hospitalized children in rural Kenya: comparison of weight for height and mid upper arm circumference. JAMA 294: 591-597.
43. Brent AJ, Oundo JO, Mwangi I, Ochola L, Lowe B, et al. (2006) Salmonella bacteremia in Kenyan children. Pediatr Infect Dis J 25: 230-236.
44. Reyburn H, Mwakasungula E, Chonya S, Mtei F, Bygbjerg I, et al. (2008) Clinical assessment and treatment in paediatric wards in the north-east of the United Republic of Tanzania. Bull World Health Organ 86: 132-139.
45. Makani J, Matuja W, Liyombo E, Snow RW, Marsh K, et al. (2003) Admission diagnosis of cerebral malaria in adults in an endemic area of Tanzania: implications and clinical description. QJM 96: 355-362.
46. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, et al. (2004) Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 329: 1212.